O-P R Hamnvik

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4119527/publications.pdf

Version: 2024-02-01

46 papers 1,893 citations

393982 19 h-index 38 g-index

46 all docs

46 docs citations

46 times ranked

3213 citing authors

#	Article	IF	CITATIONS
1	Telemedicine and Inequities in Health Care Access: The Example of Transgender Health. Transgender Health, 2022, 7, 113-116.	1.2	25
2	A targeted approach to phosphoinositide-3-kinase/Akt/mammalian target of rapamycin-induced hyperglycemia. Current Problems in Cancer, 2022, 46, 100776.	1.0	7
3	Lessons Learned From Establishing an Oncoendocrinology Clinic. Endocrine Practice, 2022, 28, 118-121.	1.1	O
4	Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis. Cancer Immunology, Immunotherapy, 2022, 71, 1795-1812.	2.0	31
5	Changes in bone turnover markers (BTM) and association with outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) +/-docetaxel (D) in CHAARTED (ECOG-ACRIN E3805) Journal of Clinical Oncology, 2022, 40, 145-145.	0.8	0
6	Gender Reference Use in Spirometry for Transgender Patients. Annals of the American Thoracic Society, 2021, 18, 537-540.	1.5	4
7	Cardiovascular Disease Risk Among Transgender People with HIV. Current HIV/AIDS Reports, 2021, 18, 407-423.	1.1	3
8	Teriparatide in individuals with a prior history of radiation therapyâ€"a case series. Archives of Osteoporosis, 2021, 16, 149.	1.0	0
9	A flipped classroom in graduate medical education. Clinical Teacher, 2020, 17, 195-199.	0.4	24
10	Challenges with Accuracy of Gender Fields in Identifying Transgender Patients in Electronic Health Records. Journal of General Internal Medicine, 2020, 35, 3724-3725.	1.3	7
11	NEJM Knowledge+ Question of the Week: A Novel Virtual Learning Community Effectively Utilizing an Online Discussion Forum. Medical Teacher, 2019, 41, 1270-1276.	1.0	3
12	Bone Densitometry in Transgender and Gender Non-Conforming (TGNC) Individuals: 2019 ISCD Official Position. Journal of Clinical Densitometry, 2019, 22, 544-553.	0.5	41
13	NEJM Knowledge+ Pain Management and Opioids — A New Adaptive Learning Module. New England Journal of Medicine, 2019, 380, 1576-1577.	13.9	12
14	A case of Graves' ophthalmopathy associated with pembrolizumab (Keytruda) therapy. Journal of AAPOS, 2018, 22, 310-312.	0.2	15
15	Risk Factors for New Hypothyroidism During Tyrosine Kinase Inhibitor Therapy in Advanced Nonthyroidal Cancer Patients. Thyroid, 2018, 28, 437-444.	2.4	31
16	Hypothyroidism During Tyrosine Kinase Inhibitor Therapy Is Associated with Longer Survival in Patients with Advanced Nonthyroidal Cancers. Thyroid, 2018, 28, 445-453.	2.4	29
17	Differential Effects of Oral and Intravenous Lipid Administration on Key Molecules Related to Energy Homeostasis. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1989-1997.	1.8	18
18	Adiponectin administration prevents weight gain and glycemic profile changes in diet-induced obese immune deficient Rag1 \hat{a} '/ \hat{a} ' mice lacking mature lymphocytes. Metabolism: Clinical and Experimental, 2016, 65, 1720-1730.	1.5	15

#	Article	IF	CITATIONS
19	Thyroid Complications of Cancer Therapy: An Increasing Challenge. AACE Clinical Case Reports, 2016, 2, e272-e273.	0.4	O
20	Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy. JAMA Oncology, 2016, 2, 500.	3.4	94
21	The adverse effects of androgen-deprivation therapy: Comparison between gonadotropin-releasing hormone agonists and orchiectomy in the SEER-Medicare population. Journal of Clinical Oncology, 2016, 34, 304-304.	0.8	0
22	Omentin-1 levels are reduced by pharmacologic doses of leptin, but remain unaffected by energy deprivation and display no day–night variation. International Journal of Obesity, 2015, 39, 260-264.	1.6	12
23	Lack of mature lymphocytes results in obese but metabolically healthy mice when fed a high-fat diet. International Journal of Obesity, 2015, 39, 1548-1557.	1.6	26
24	Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer, 2015, 121, 311-319.	2.0	165
25	Angiotensin System Inhibitors and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2015, 21, 2471-2479.	3.2	109
26	Springing a Leak. New England Journal of Medicine, 2015, 373, 1362-1367.	13.9	0
27	Wasting Away. New England Journal of Medicine, 2014, 370, 959-966.	13.9	9
28	Circulating alanine transaminase (ALT) and \hat{l}^3 -glutamyl transferase (GGT), but not fetuin-A, are associated with metabolic risk factors, at baseline and at two-year follow-up: The prospective Cyprus Metabolism Study. Metabolism: Clinical and Experimental, 2014, 63, 773-782.	1.5	36
29	Wasting Away. New England Journal of Medicine, 2014, 370, e12.	13.9	3
30	Effect of baseline characteristics, including antihypertensive therapy, on survival and hypertension during treatment with vascular endothelial growth factor (VEGF) signaling pathway inhibitors (VSP-Is) Journal of Clinical Oncology, 2014, 32, 9639-9639.	0.8	0
31	Leptin's Role in Lipodystrophic and Nonlipodystrophic Insulin-Resistant and Diabetic Individuals. Endocrine Reviews, 2013, 34, 377-412.	8.9	212
32	Gender Dimorphism and Lack of Day/Night Variation or Effects of Energy Deprivation on Undercarboxylated Osteocalcin Levels in Humans. Obesity, 2013, 21, E527-32.	1.5	1
33	Response: Re: Thyroid Dysfunction from Antineoplastic Agents. Journal of the National Cancer Institute, 2012, 104, 423-423.	3.0	1
34	Leptin as a Modulator of Neuroendocrine Function in Humans. Yonsei Medical Journal, 2012, 53, 671.	0.9	54
35	Optimizing bone health in anorexia nervosa and hypothalamic amenorrhea: new trials and tribulations. Metabolism: Clinical and Experimental, 2012, 61, 899-905.	1.5	13
36	Soluble leptin receptor and leptin are associated with baseline adiposity and metabolic risk factors, and predict adiposity, metabolic syndrome, and glucose levels at 2-year follow-up: the Cyprus Metabolism Prospective Cohort Study. Metabolism: Clinical and Experimental, 2011, 60, 987-993.	1.5	41

3

#	Article	IF	CITATIONS
37	Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. Metabolism: Clinical and Experimental, 2011, 60, 1363-1371.	1.5	79
38	Circulating lipocalin 2 is associated with body fat distribution at baseline but is not an independent predictor of insulin resistance: the prospective Cyprus Metabolism Study. European Journal of Endocrinology, 2011, 165, 805-812.	1.9	36
39	Thyroid Dysfunction from Antineoplastic Agents. Journal of the National Cancer Institute, 2011, 103, 1572-1587.	3.0	143
40	Leptin in human physiology and pathophysiology. American Journal of Physiology - Endocrinology and Metabolism, 2011, 301, E567-E584.	1.8	458
41	Morbidity and mortality in patients with craniopharyngioma after surgery. Clinical Endocrinology, 2010, 73, 516-521.	1.2	64
42	Lymphocytic hypophysitis with diabetes insipidus in a young man. Nature Reviews Endocrinology, 2010, 6, 464-470.	4.3	16
43	Meticillin-sensitive Staphylococcus aureus costochondritis in a healthy man. Nature Reviews Rheumatology, 2009, 5, 708-710.	3.5	1
44	Balancing Risk and Benefit with Oral Hypoglycemic Drugs. Mount Sinai Journal of Medicine, 2009, 76, 234-243.	1.9	32
45	Glycemic Targets for Patients with Type 2 Diabetes Mellitus. Mount Sinai Journal of Medicine, 2009, 76, 227-233.	1.9	7
46	Diffuse large Bâ€eell lymphoma with isolated bone marrow involvement presenting with secondary cold agglutinin disease. International Journal of Laboratory Hematology, 2008, 30, 444-445.	0.7	16